Steiner CA, Berinstein JA, Louissaint J, et al. - Since intestinal strictures are a common complication of Crohn disease (CD), researchers sought to provide a comprehensive systematic review of studies evaluating biomarkers that may anticipate or diagnose CD-associated strictures. They conducted a systematic review of PubMed, EMBASE, ISI Web of Science, Cochrane Library, and Scopus to identify citations pertaining to biomarkers of intestinal fibrosis through July 6, 2020, that utilized a reference standard of full-thickness histopathology and/or cross-sectional imaging and/or endoscopy. Promising markers involve cartilage oligomeric matrix protein, hepatocyte growth factor activator, and lower levels of microRNA-19-3p, as well as multiple anti-flagellin antibodies. There is a scarcity of well-defined research on biomarkers of intestinal stricture. A research priority is the development of reliable and accurate biomarkers of stricture. Biomarkers can help with the clinical management of CD patients by stratifying and monitoring patients during clinical trials of future antifibrotic drug candidates.